# Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies

> **NCT02485717** · PHASE3 · COMPLETED · sponsor: **ParaPRO LLC** · enrollment: 291 (actual)

## Conditions studied

- Scabies

## Interventions

- **DRUG:** spinosad topical suspension, 0.9%
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02485717
- **Lead sponsor:** ParaPRO LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-02
- **Primary completion:** 2018-06-25
- **Final completion:** 2018-06-25
- **Target enrollment:** 291 (ACTUAL)
- **Last updated:** 2021-05-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02485717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02485717, "Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02485717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*